Gateway’s Chair of Rural Mental Health, Dr. Craig Hudson, has recently published a clinical study in Hindawi’s Parkinson’s Disease Journal. The study involved 16 participants with Parkinson’s disease who were studied over the course of 6 weeks. Participant’s received a low dose of haloperidol, a medication known to increase sensitivity of dopamine receptors in animals, in conjunction with their regular levodopa medication. The SPES/SCOPA scale, which assesses motor impairments and disabilities in Parkinson’s disease, was used as a method of measurement. Hudson’s study found the SPES/SCOPA scores to decrease after just 1 week of low dose haloperidol treatment, suggesting that haloperidol increases sensitivity of dopamine receptors in humans. This is beneficial as the levodopa medication used in the management of Parkinson’s Disease can have negative side effects. By introducing haloperidol as a Parkinson’s Disease treatment option, levodopa may be able to be decreased, and therefore decrease the negative side effects. To read Craig Hudson’s full article, visit this link: Parkinson's Study.